321 related articles for article (PubMed ID: 25829187)
1. Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor β in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension.
Stefanantoni K; Sciarra I; Vasile M; Badagliacca R; Poscia R; Pendolino M; Alessandri C; Vizza CD; Valesini G; Riccieri V
Reumatismo; 2015 Mar; 66(4):270-6. PubMed ID: 25829187
[TBL] [Abstract][Full Text] [Related]
2. Serum levels, tissue expression and cellular secretion of macrophage migration inhibitory factor in limited and diffuse systemic sclerosis.
Corallo C; Paulesu L; Cutolo M; Ietta F; Carotenuto C; Mannelli C; Romagnoli R; Nuti R; Giordano N
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S98-105. PubMed ID: 26005773
[TBL] [Abstract][Full Text] [Related]
3. Macrophage migration inhibitory factor may contribute to vasculopathy in systemic sclerosis.
Becker H; Willeke P; Schotte H; Domschke W; Gaubitz M
Clin Rheumatol; 2008 Oct; 27(10):1307-11. PubMed ID: 18618071
[TBL] [Abstract][Full Text] [Related]
4. Pilot study: elevated circulating levels of the proinflammatory cytokine macrophage migration inhibitory factor in patients with chronic spinal cord injury.
Stein A; Panjwani A; Sison C; Rosen L; Chugh R; Metz C; Bank M; Bloom O
Arch Phys Med Rehabil; 2013 Aug; 94(8):1498-507. PubMed ID: 23618747
[TBL] [Abstract][Full Text] [Related]
5. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.
Thakkar V; Stevens W; Prior D; Rabusa C; Sahhar J; Walker JG; Roddy J; Lester S; Rischmueller M; Zochling J; Nash P; Gabbay E; Youssef P; Proudman SM; Nikpour M
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):129-136. PubMed ID: 27214686
[TBL] [Abstract][Full Text] [Related]
6. Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension.
Kylhammar D; Hesselstrand R; Nielsen S; Scheele C; Rådegran G
Scand J Rheumatol; 2018 Jul; 47(4):319-324. PubMed ID: 29528272
[TBL] [Abstract][Full Text] [Related]
7. Macrophage migration inhibitory factor polymorphisms are a potential susceptibility marker in systemic sclerosis from southern Mexican population: association with MIF mRNA expression and cytokine profile.
Baños-Hernández CJ; Navarro-Zarza JE; Bucala R; Hernández-Bello J; Parra-Rojas I; Ramírez-Dueñas MG; García-Arellano S; Hernández-Palma LA; Machado-Sulbarán AC; Muñoz-Valle JF
Clin Rheumatol; 2019 Jun; 38(6):1643-1654. PubMed ID: 30747392
[TBL] [Abstract][Full Text] [Related]
8. An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis.
Bossini-Castillo L; Campillo-Davó D; López-Isac E; Carmona FD; Simeon CP; Carreira P; Callejas-Rubio JL; Castellví I; Fernández-Nebro A; Rodríguez-Rodríguez L; Rubio-Rivas M; García-Hernández FJ; Madroñero AB; Beretta L; Santaniello A; Lunardi C; Airó P; Hoffmann-Vold AM; Kreuter A; Riemekasten G; Witte T; Hunzelmann N; Vonk MC; Voskuyl AE; de Vries-Bouwstra J; Shiels P; Herrick A; Worthington J; Radstake TRDJ; Martin J;
J Rheumatol; 2017 Oct; 44(10):1453-1457. PubMed ID: 28668810
[TBL] [Abstract][Full Text] [Related]
9. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis.
Becker MO; Kill A; Kutsche M; Guenther J; Rose A; Tabeling C; Witzenrath M; Kühl AA; Heidecke H; Ghofrani HA; Tiede H; Schermuly RT; Nickel N; Hoeper MM; Lukitsch I; Gollasch M; Kuebler WM; Bock S; Burmester GR; Dragun D; Riemekasten G
Am J Respir Crit Care Med; 2014 Oct; 190(7):808-17. PubMed ID: 25181620
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis.
Shirai Y; Okazaki Y; Inoue Y; Tamura Y; Yasuoka H; Takeuchi T; Kuwana M
Arthritis Rheumatol; 2015 Feb; 67(2):498-507. PubMed ID: 25385504
[TBL] [Abstract][Full Text] [Related]
11. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.
Williams MH; Handler CE; Akram R; Smith CJ; Das C; Smee J; Nair D; Denton CP; Black CM; Coghlan JG
Eur Heart J; 2006 Jun; 27(12):1485-94. PubMed ID: 16682379
[TBL] [Abstract][Full Text] [Related]
12. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis.
Cavagna L; Caporali R; Klersy C; Ghio S; Albertini R; Scelsi L; Moratti R; Bonino C; Montecucco C
J Rheumatol; 2010 Oct; 37(10):2064-70. PubMed ID: 20634241
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
Colaci M; Giuggioli D; Sebastiani M; Manfredi A; Lumetti F; Luppi F; Cerri S; Ferri C
Reumatismo; 2015 Dec; 67(4):149-55. PubMed ID: 27215180
[TBL] [Abstract][Full Text] [Related]
14. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension.
Tamby MC; Chanseaud Y; Humbert M; Fermanian J; Guilpain P; Garcia-de-la-Peña-Lefebvre P; Brunet S; Servettaz A; Weill B; Simonneau G; Guillevin L; Boissier MC; Mouthon L
Thorax; 2005 Sep; 60(9):765-72. PubMed ID: 16135682
[TBL] [Abstract][Full Text] [Related]
15. Serum apelin levels: clinical association with vascular involvements in patients with systemic sclerosis.
Aozasa N; Asano Y; Akamata K; Noda S; Masui Y; Yamada D; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):37-42. PubMed ID: 22112232
[TBL] [Abstract][Full Text] [Related]
16. Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations.
Thakkar V; Patterson KA; Stevens W; Wilson M; Roddy J; Sahhar J; Proudman S; Hissaria P; Nikpour M
Clin Rheumatol; 2018 Jun; 37(6):1563-1571. PubMed ID: 29687288
[TBL] [Abstract][Full Text] [Related]
17. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
[TBL] [Abstract][Full Text] [Related]
18. Impaired bone morphogenetic protein receptor II signaling in a transforming growth factor-β-dependent mouse model of pulmonary hypertension and in systemic sclerosis.
Gilbane AJ; Derrett-Smith E; Trinder SL; Good RB; Pearce A; Denton CP; Holmes AM
Am J Respir Crit Care Med; 2015 Mar; 191(6):665-77. PubMed ID: 25606692
[TBL] [Abstract][Full Text] [Related]
19. Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry.
Hinchcliff M; Khanna S; Hsu VM; Lee J; Almagor O; Chang RW; Steen V; Chung L;
Semin Arthritis Rheum; 2015 Dec; 45(3):309-14. PubMed ID: 26210782
[TBL] [Abstract][Full Text] [Related]
20. Serum omentin levels: A possible contribution to vascular involvement in patients with systemic sclerosis.
Miura S; Asano Y; Saigusa R; Yamashita T; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Sato S; Kadono T
J Dermatol; 2015 May; 42(5):461-6. PubMed ID: 25766303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
